Commercial Channels

Financial commitment further strengthens IntegriChain’s platform as a source for pharma manufacturers' commercialization and market access goals.

Bill Roth provides insight as to how where chief commercial officers and access leaders can plan for a profitable product lifecycle.

How drugmakers can better harness real-world evidence to drive their clinical and commercial objectives, while also providing greater clarity for healthcare providers and improved access to therapy for the patients they serve.

The conference will focus on the full breadth of commercialization strategies and operations.

A look into ways to approach change management using three factors.

The company anticipates that the offering will help maximize life sciences brands’ commercial potential.

How the ‘fight-for-the-dollar’ is coming and likely will impact the bundled pricing of industry stakeholders.

Sy Pretorius, COO & president of outsourced solutions at Eversana, dives into his new role in the space, after being a veteran in the clinical development sector.

New PC column explores commercialization trends and how pharma can adjust to the new squeeze of market, regulatory, pricing, and gross-to-net pressures.

The latest IT offerings for sales force automation—including new AI tools—promise a more effective pharma sales process.

How pharma can harness digitalization all the way through commercialization

Document reveals that 20 of 28 of participating Big Pharma manufacturers saw their DIO increase by an average of 5%, suggesting that large amounts of inventory do not necessarily offer protection from running low on medication.

New federal law introduces significant changes in the design of pharmacy benefit plans with aims to level the playing field between PBMs and their employee healthcare benefit plan clients.

Acquisition is expected to drive organization’s ‘next phase of growth.’

Site expected to support growth of advanced analytics and data science team.

Acquisition of Evolution Road expands company’s omnichannel know-how

Stakeholders are investing heavily in their ability to curate appropriate data sets and devise advanced data-analytics capabilities to harness real-world evidence (RWE) across the entire pharma lifecycle—from drug discovery and development through product launch and commercialization

How to make commercial AI actionable in the last mile, helping to better realize data science investment and improve customer engagement

How biopharma commercial teams can leverage machine learning techniques to improve targeting of HCPs and patients

Product commercialization in Canada is by no means simple, but the end result presents its advantages

Healthcare marketing agency acquisition augments company’s commercialization portfolio

AZ’s Greg Rossi talks about the company’s oncology activities and his vision for the future of cancer treatment

With the business model changing and the patent cliff looming, Ashfield Engage's Chris Savage talks about what these upheavals mean for pharma companies, their sales reps, and their patients

Willis Chandler, AmerisourceBergen’s recently named President of Biopharma Services, Strategic Global Sourcing and Commercial Solutions, talks about the new investments AB is making to build out its capabilities and its new cell and gene therapy service line.

Private-equity-funded conglomerate will offer life sciences commercialization services

Configuration-driven SaaS, powered by modern data management technology, can enable orphan drug manufacturers to form effective commercial strategies

Maria Whitman, global head of ZS’s pharmaceutical and biotech practice, talks about the upheaval of the pharma business model and what it means for sales reps; the current skills gap in the marketplace; and how mega-mergers could soon be back on the agenda

Leveraging the value healthcare professionals place on scientific content

Catherine Humphries sheds light on three key market access challenges within the ophthalmology biosimilars space.

By 2024 oncology therapeutic sales will hit $250 billion worldwide, and there will be more than 22 million cancer survivors. But commercializing how these critical therapies come to market to help patients hasn’t changed much in the past 20 years. The industry must do more, write Anne Marie Robertson and Ellen Cappellino